TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00066482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children \< 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC \> 5,000/uL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESNA
Description: Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
Study: NCT03163355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a gelling agent
Description: Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: a gelling agent
Description: Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
Study: NCT00217646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study: NCT03493230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quantification of BRAF and NRAS mutation
Description: Quantification of cell-free BRAF and NRAS mutations with digital PCR
Study: NCT04035057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behaviorally Enhanced Training
Description: Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Didactic Training
Description: Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
Study: NCT04285255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: opioids anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: alpha 2 agonist with sedative, analgesic effect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique subcostal transversus abdominis plane block
Description: Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique subcostal transversus abdominis plane block
Description: Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: infusion of lidocaine 2%(1mg/kg/h)
Study: NCT01592331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5508887
Description: Single oral dose
Study: NCT00282893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transluminal ballooning
Study: NCT04902274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
Study: NCT00282893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: currently existing therapies for the treatment of vasospasm
Study: NCT04902274

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Therapy
Description: After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
Study: NCT04038970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN019, 5mg/kg
Description: Solution, intravenous, 5 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN019, 10 mg/kg
Description: Solution, intravenous, 10 mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, intravenous, Placebo

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
Study: NCT01965210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small non-supplemented rye
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat bread
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat bread
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat bread
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat bread
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat bread
Description: In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
Study: NCT05085925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral mindfulness intervention
Description: The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral mindfulness intervention after 3-month wait list
Description: Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
Study: NCT04636489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland barley β-glucan dietary supplement
Description: 100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: Placebo with a similar appearance and taste to highland barley β-glucan supplement
Study: NCT01534026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Current dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of aspirin
Description: Stopping current dose of aspirin
Study: NCT04063774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dengue calculator
Description: Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
Study: NCT04309916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40mg tablet
Study: NCT02498834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video and Question Prompt List
Description: Educational Video and Question Prompt List
Study: NCT02317926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Plus Liothyronine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desiccated Thyroid Extract
Study: NCT02650050

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Micropulsed laser photocoagulation
Description: Micropulsed laser photocoagulation after 3 anti-VEGF injections

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Micropulsed laser photocoagulation
Description: Micropulsed laser photocoagulation after 3 anti-VEGF injections
Study: NCT00772590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Tablets, 400mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-immune Bovine Colostrum
Description: Tablet, 1800mg, twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: raltegravir placebo
Description: One tablet, twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyper-immune Bovine Colostrum placebo
Description: Three tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and hyper-immune bovine colostrum
Description: 400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
Study: NCT01180348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulift
Description: Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
Study: NCT01118364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving

Intervention type: OTHER
Group type: OTHER
Intervention: tobacco
Description: a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving
Study: NCT00026143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00551252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate plus Gemcitabine
Description: Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
Study: NCT04102579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active dosage form
Study: NCT02572557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruFreeze Spray CryoTherapy
Description: TruFreeze Spray CryoTherapy using liquid nitrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen
Description: TruFreeze Spray CryoTherapy using liquid nitrogen
Study: NCT05899686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanic Stimulus
Description: 5 second 100 Hz 70 mA tetanic stimulus will be applied to three different anatomical locations in each subject.
Study: NCT03778879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX872-B
Description: CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
Study: NCT04322123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Product
Description: Hydroxychloroquine 400 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + azithromycin
Description: Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
Study: NCT03322280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE combined with iodine-125 seeds implantation
Description: Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Only conventional TACE with lipiodol and chemotherapy drugs was performed.
Study: NCT02874495

Intervention type: BEHAVIORAL
Intervention: Psychological tests
Description: Related to affective and cognitive dimensions of pain.
Study: NCT02621957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
Study: NCT02966756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study: NCT04284345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Pd/Pa
Description: Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement.
Study: NCT00604032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atralin (tretinoin) Gel, 0.05%
Description: Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
Study: NCT03740308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locally Made Zirconia Crowns
Description: Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZR Zirconia Crwons NuSmile ® Crowns
Description: Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
Study: NCT03169218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
Study: NCT01048814

Intervention type: OTHER
Intervention: ChemoFx
Description: Chemoresponse Marker Assay
Study: NCT01865955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound applied to the lumbar region to determine spinal needle placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The spinal needle
Study: NCT03182335

Intervention type: OTHER
Intervention: sedation awakening trial
Description: vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
Study: NCT03155789

Intervention type: PROCEDURE
Intervention: Lumbar Fusion
Description: Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion

Intervention type: PROCEDURE
Intervention: Lumbar Fusion
Description: Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion

Intervention type: PROCEDURE
Intervention: Lumbar Fusion
Description: Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion
Study: NCT02874495

Intervention type: BEHAVIORAL
Intervention: Psychological tests
Description: Related to affective and cognitive dimensions of pain.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability.